The European LeukemiaNet (ELN) has updated its recommendations for treating chronic myeloid leukemia (CML) to reflect the significant advancements in therapy over the past 7 years. The new guidelines aim to achieve normal life expectancy and stable deep molecular response (DMR) in patients with chronic phase (CP) CML, with the goal of discontinuing treatment for treatment-free remission (TFR). The first-line treatment is a tyrosine kinase inhibitor (TKI), with generic imatinib being the cost-effective initial option. Various contraindications and side effects of TKIs should be considered, and patient risk status at diagnosis should be assessed using the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction (qPCR). Treatment changes are recommended when intolerance cannot be ameliorated or molecular milestones are not reached. Allogeneic stem cell transplantation remains a therapeutic option, particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR, aiming for TFR. The recommendations are based on high-quality evidence and consensus among an international panel of experts.The European LeukemiaNet (ELN) has updated its recommendations for treating chronic myeloid leukemia (CML) to reflect the significant advancements in therapy over the past 7 years. The new guidelines aim to achieve normal life expectancy and stable deep molecular response (DMR) in patients with chronic phase (CP) CML, with the goal of discontinuing treatment for treatment-free remission (TFR). The first-line treatment is a tyrosine kinase inhibitor (TKI), with generic imatinib being the cost-effective initial option. Various contraindications and side effects of TKIs should be considered, and patient risk status at diagnosis should be assessed using the new EUTOS long-term survival (ELTS)-score. Monitoring of response should be done by quantitative polymerase chain reaction (qPCR). Treatment changes are recommended when intolerance cannot be ameliorated or molecular milestones are not reached. Allogeneic stem cell transplantation remains a therapeutic option, particularly for advanced phase CML. TKI treatment should be withheld during pregnancy. Treatment discontinuation may be considered in patients with durable DMR, aiming for TFR. The recommendations are based on high-quality evidence and consensus among an international panel of experts.